Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndrome: A new approach to treatment

Neurology

Volumn 46, Issue 6, 1996, Pages 1644-1651

  Yuki, Nobuhiro ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Saitoh Memorial Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; DNA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PHENYLALANINE; RHEUMATOID FACTOR; TRYPTOPHAN;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOADSORBENT; IMMUNOADSORPTION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; SUBCLAVIAN STEAL SYNDROME;

EID: 0029973291     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.6.1644     Document Type: Article

References (36)

1. Arnason BGW, Soliven B. Acute inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, et al, eds. Peripheral neuropathy. 3rd ed. Philadelphia; Saunders, 1993:1437-1497.
2. Berlit P, Rakicky J. The Miller Fisher syndrome: review of the literature. J Clin Neuroophthalmol 1992;12:57-63.
3. Guillain-Barré Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-1104.
4. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22:753-761.
5. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow up. Ann Neurol 1992;32:94-97.
6. Irvine AT, Tribbles J. Treatment of Fisher's variant of Guillain-Barré syndrome by exchange transfusion. Can J Neurol Sci 1981;8:49-50.
7. Littlewood R, Bajada S. Successful plasmapheresis in the Miller-Fisher [sic] syndrome. Br Med J 1981;282:778.
8. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-679.
9. Yuki N, Sato S, Tsuji S, et al. Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology 1993;43:414-417.
10. Willison HJ, Veitch J, Paterson G, Kennedy PGE. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 1993;56:204-206.
11. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-1917.
12. Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 1994;50:159-165.
13. Yuki N, Taki T, Takahashi M, et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994;36:791-793.
14. Jacobs BC, Endtz HPh, van der Meché FGA, et al. Serum anti-GQ1b IgG antibodies recognize surface epitope on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol 1995;37:260-264.
15. Roberts M, Willison H, Vincent A, Newsom-Davis J. Serum factor in Miller-Fisher [sic] variant of Guillain-Barré syndrome and neurotransmitter release. Lancet 1994;343:454-455.
16. Yuki N, Miyatake T, Ohsawa T. Beneficial effect of plasmapheresis on Fisher's syndrome. Muscle Nerve 1993;16:1267-1268.
17. Yamazaki Z, Fujimori Y, Takahama T, et al. Basic studies on a new immunoadsorbent (I-02). In: Oda T, ed. Therapeutic plasmapheresis (II). Stuttgart: Schattauer Verlag, 1982:111-115.
18. Maeda K, Sezaki R, Shinzato T, et al. Clinical application of newly developed immunoadsorbent resin for regeneration of plasma from autoimmune disease patients. In: Oda T, ed. Therapeutic Plasmapheresis (III). Stuttgart: Schattauer Verlag, 1983:219-223.
19. Sato T, Anno M, Arai K, et al. In vitro removal of antiacetylcholine receptor antibodies with a new immunosorbent in sera from myasthenia gravis. In: Atsumi K, Maekawa M, Ota K, eds. Progress in artificial organs. Cleveland: ISAO Press, 1983:719-722.
20. Heininger K, Hendricks M, Toyka KV. Myasthenia gravis: a new semiselective procedure to remove acetylcholine-receptor-autoantibodies from plasma. Plasma Ther Transfus Technol 1985;6:771-775.
21. Jimenez C, Rosenow F, Grieb P, et al. Adsorption therapy with tryptophan-conjugated polyvinyl alcohol gels in 10 patients with acute Guillain-Barré syndrome. Transfus Sci 1993; 14:9-11.
22. Shinoda T, Koh C-S, Arakura H, et al. Immunoadsorption plasmapheresis in Guillain-Barré syndrome. In: Agishi T, Kawamura A, Mineshima M, eds. Therapeutic plasmapheresis (XII). Utrecht: VSP, 1993:531-534.
23. Koh C-S, Shinoda T, Shimada K, et al. Immunoadsorption plasmapheresis and plasma exchange in Miller Fisher syndrome. In: Agishi T, Kawamura A, Mineshima M, eds. Therapeutic plasmapheresis (XII). Utrecht: VSP, 1993:557-560.
24. Shimizu H, Ishikawa K, Hirabayashi K, et al. Plasma immunoadsorption therapy in Fisher's syndrome. In: Agishi T, Kawamura A, Mineshima M, eds. Therapeutic plasmapheresis (XII). Utrecht: VSP, 1993:581-583.
25. Yuki N, Miyatani N, Sato S, et al. Acute relapsing sensory neuropathy associated with IgM antibody against B-series gangliosides containing a GalNAcβ1-4(Gal3-2αNeuAc8-2αNeuAc)β1 configuration. Neurology 1992;42:686-689.
26. Yuki N, Sato S, Miyatake T, et al. Motoneuron-disease-like disorder after ganglioside therapy. Lancet 1991;337:1109-1110.
27. Yuki N, Ichihashi Y, Taki T. Subclass of IgG antibody to GM1 epitope-bearing lipopolysaccharide of Campylobacter jejuni in patients with Guillain-Barré syndrome. J Neuroimmunol 1995;60:161-164.
28. Shibuya N, Andou K, Goto I. A nationwide questionnaire on efficiency of plasmapheresis in Guillain-Barré syndrome. Annual Report of the Neuroimmunological Diseases Research Committee, the Ministry of Health and Welfare, Japan. 1990: 191-194. [in Japanese with English abstract]
29. Goto H, Tujino A, Fujishita S, et al. Tryptophan-PVA gel effectively removes antibodies against gangliosides. Jpn J Apheresis 1994;13:164-165.
30. Ilyas AA, Willison HJ, Quarles RH, et al. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 1988; 23:440-447.
31. Yuki N, Yamada M, Sato S, et al. Association of IgG anti-GD1a antibody with severe Guillain-Barré syndrome. Muscle Nerve 1993;16:642-647.
32. Bleck TP. IVIg for GBS: potential problems in the alphabet soup. Neurology 1993;43:857-858.
33. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
34. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-590.
35. Kozaki Y, Tanford C. The solubility of amino acids and two glycine peptides in aqueous ethanol and dioxane solutions. J Biol Chem 1971;246:2211-2217.
36. Yuki N, Sato S, Tsuji S, et al. An immunologie abnormality common to BickerstafFs brain stem encephalitis and Fisher's syndrome. J Neurol Sci 1993;118:83-87.